Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

The Liver Meeting website

11/20/16

AASLD 2014: Entecavir and Tenofovir Work Well for People with Resistant Hepatitis B Virus

A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the ENTEBE study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Another study, however, showed that for some resistant patients, tenofovir worked equally well on its own.

Read more:

Coverage of the 2015 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.

Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver  cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.

Full listing by topic

Liver Meeting website

11/23/15

AASLD 2014: Many Hepatitis C Patients with Cirrhosis or Advanced Fibrosis Face Liver Failure

Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within 5 years, and 23% and 11%, respectively, died, according to a study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. These findings underscore the urgent need for treatment for such individuals.

Read more:

AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.

Read more:

AASLD 2014: Sofosbuvir/ Ledipasvir Cures Most Previously Treated HCV Patients with Cirrhosis

Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of therapy with first-generation HCV protease inhibitors had a sustained virological response rate of 97% when retreated with sofosbuvir/ledipasvir (Harvoni) for 24 weeks, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Sofosbuvir/ledipasvir also worked worked well for people previously treated with other sofosbuvir-containing regimens.

Read more:

AASLD 2014: Experimental siRNA Therapy Lowers HBsAg Levels in Hepatitis B Patients

ARC-520, a novel therapy using short interfering RNA, appeared safe and was associated with a reduction in hepatitis B surface antigen levels in chronic hepatitis B patients taking entecavir, according to Phase 2a study results reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston.

Read more:

AASLD 2014: Screening Baby Boomers for HCV More Effective than Risk-based Testing

Age cohort screening for hepatitis C virus (HCV) identified 4 times as many people as prevailing screening protocols and can be "feasibly implemented," according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston.

Read more: